- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05415904
Hantavirus Nephropathy in North-Eastern France : Severity Risk Factors and Prognostic Tools (HANTA-NE)
Hantaviruses are emerging pathogens responsible for hemorrhagic fever with renal syndrome. Severity risks factors aren't consensual in litterature, mostly related to scandinavian cohorts. A prognostic score was created to help patient's orientation in healthcare system but wasn't independantly validated (Hentzien, Emerging infectious diseases 2018).
This retrospective cohort of hantavirus infected hospitalized adults patients in the north-eastern quarter of France between 2013 and 2022 will specify the kidney damage during infection and risk factors for a severe form (defined par acute kidney injury KDIGO 3). The previous prognostic score performance will be evaluated in this cohort.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Förväntat)
Kontakter och platser
Studieorter
-
-
-
Nancy, Frankrike, 54000
- Central Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- hantavirus proven by serology infection
- age above 18 years
- Hospitalisation
Exclusion Criteria:
- age under 18 years
- fulfill opposition form
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: Kohort
- Tidsperspektiv: Retrospektiv
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
HANTA-NE
All adult patient hospitalized for hantavirus infection between 01/01/2013 and 31/12/2022 in North Eastern France
|
Observational cohort study
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Creatinin level
Tidsram: Through study completion, an average of 2 years
|
Acute Kidney injury KDIGO 3
|
Through study completion, an average of 2 years
|
Hemorrhagic syndrome
Tidsram: Through study completion, an average of 2 years
|
Major bleeding requiring blood transfusion
|
Through study completion, an average of 2 years
|
Death
Tidsram: Through study completion, an average of 2 years
|
Death
|
Through study completion, an average of 2 years
|
Hospitalisation in intensive care unit
Tidsram: Through study completion, an average of 2 years
|
Hospitalisation in intensive care unit
|
Through study completion, an average of 2 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Score performance to predict severity
Tidsram: Through study completion, an average of 2 years
|
Correlation between severity predicted by the score and bio-clinical severity during hospitalization. Score composition : Hematuria = 7 Visual disorders = 8 Leucocyte count > 10 x 10^9 cells/L = 9 Nephrotoxic drug exposure (NSAID, iodinated contrast media, diuretics, renin angiotensin aldosterone system inhibitors, aminoglycosides, glycopeptides) = 10 Thrombocytopenia < or = 90 000/mm3 = 11 Risk group according score scale 0-10 Low risk 11-19 intermediate risk 20-45 high risk |
Through study completion, an average of 2 years
|
Hypotension
Tidsram: Through study completion, an average of 2 years
|
Lowest systolic blood presure during hospitalisation < 90mmHg
|
Through study completion, an average of 2 years
|
Proteinuria
Tidsram: Through study completion,an average of 2 years
|
Proteinuria during hospitalisation defined by proteinuria/creatininuria above 500 mg/g or equivalent
|
Through study completion,an average of 2 years
|
Urinary dipstick
Tidsram: Through study completion, an average of 2 years
|
Leucocyturia or hematuria
|
Through study completion, an average of 2 years
|
ALAT, ASAT
Tidsram: Through study completion, an average of 2 years
|
Liver cytolysis
|
Through study completion, an average of 2 years
|
calcium
Tidsram: Through study completion, an average of 2 years
|
hypocalcemia, hypercalcemia
|
Through study completion, an average of 2 years
|
phosphorus
Tidsram: Through study completion, an average of 2 years
|
hypophaspahtaemia, hyperphasphatemia
|
Through study completion, an average of 2 years
|
potassium
Tidsram: Through study completion, an average of 2 years
|
hypokaliemia, hyperkaliemia
|
Through study completion, an average of 2 years
|
sodium
Tidsram: Through study completion, an average of 2 years
|
blood sodium level disorders
|
Through study completion, an average of 2 years
|
bicarbonate blood level
Tidsram: Through study completion, an average of 2 years
|
metabolic acidosis, metabolic alcalosis
|
Through study completion, an average of 2 years
|
Heamoglobin
Tidsram: Through study completion, an average of 2 years
|
Anemia
|
Through study completion, an average of 2 years
|
platelets level
Tidsram: Through study completion, an average of 2 years
|
thrombocytemia
|
Through study completion, an average of 2 years
|
Urine output
Tidsram: Through study completion, an average of 2 years
|
Polyruria above 3 L/day
|
Through study completion, an average of 2 years
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Alice CORBEL, M.D., Central Hospital, Nancy, France
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2022PI034
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Hantavirus Nephropathy
-
National Institute of Allergy and Infectious Diseases...AvslutadImmunisering | Hantavirus lunginfektionFörenta staterna
-
National Institute of Allergy and Infectious Diseases...AvslutadHantavirus lungsyndromFörenta staterna
-
University of New MexicoNational Institute of Allergy and Infectious Diseases (NIAID)Avslutad
-
University of New MexicoNational Institute of Allergy and Infectious Diseases (NIAID)Avslutad
-
University of CologneRekryteringHantavirusinfektioner | Hemorragisk feber med njursyndrom | Nephropathia Epidemica | Hantavirus kardiopulmonellt syndromTyskland
-
The University of The West IndiesCaribbean Health Research CouncilOkändMikroalbuminuri | Sickle Cell NephropathyJamaica
-
University of AarhusAktiv, inte rekryterandeNefrotiskt syndrom | Minimal förändringssjukdomDanmark
-
Arcispedale Santa Maria Nuova-IRCCSOkändMultipelt myelom | Akut njurskada | Cast NephropathyItalien
-
University Hospital BirminghamOrtho Biotech, Inc.; Gambro Renal Products, Inc.AvslutadMultipelt myelom | Njursvikt | Cast NephropathyStorbritannien
Kliniska prövningar på HANTA-NE
-
SEAMEO Regional Centre for Food and NutritionIndonesia University; Ministry of Health Republic of Indonesia; Health Polytechnic... och andra samarbetspartnersOkändAnemi | Stunting | Kompletterande utfodringsrekommendation | Linjär programmering | Indonesien | Spädbarn och små barn | Problem med näringsämnenIndonesien
-
University of ValenciaHospital de la RiberaOkänd
-
TakedaEA Pharma Co., Ltd.AvslutadInvolutionell osteoporosJapan
-
Medline IndustriesF2 LabsHar inte rekryterat ännuVidhäftning av den neutrala elektroden 21pad
-
University of VermontAvslutad
-
University of PennsylvaniaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Avslutad
-
University of NottinghamOkänd
-
University of MemphisNational Institute on Alcohol Abuse and Alcoholism (NIAAA)AvslutadBerusningsdrickande | Alkoholdrickande på college | Beteende och beteendemekanismer | Beteende, drickandeFörenta staterna
-
Shanghai Mental Health CenterRekryteringSchizofreni | Transkraniella växelströmsstimuleringar | Negativa symtomKina